{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T11:03:57Z","timestamp":1767092637520,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Intermed S.A. Pharmaceutical Laboratories, Greece"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.yebeh.2019.05.029","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T20:37:14Z","timestamp":1561495034000},"page":"192-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Vitamin D supplementation and bone markers in ambulatory children on long-term valproic acid therapy. A prospective interventional study"],"prefix":"10.1016","volume":"97","author":[{"given":"Margarita","family":"Papassava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iliada","family":"Nakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterini","family":"Siomou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Cholevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Challa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meropi","family":"Tzoufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yebeh.2019.05.029_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.1979.tb04771.x","article-title":"Antiepileptic drugs and vitamin D supplementation","volume":"20","author":"Offermann","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-200X.2002.01561.x","article-title":"Bone mineral status in ambulatory pediatric patients on long-term antiepileptic drug therapy","volume":"44","author":"Tsukahara","year":"2002","journal-title":"Pediatr Int"},{"issue":"8","key":"10.1016\/j.yebeh.2019.05.029_bb0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1440-1754.2004.00431.x","article-title":"Bone mineral metabolism changes in epileptic children receiving valproic acid","volume":"40","author":"\u00d6ner","year":"2004","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pediatrneurol.2006.03.004","article-title":"Adverse effects of antiepileptic drugs on bone mineral density","volume":"35","author":"Babayigit","year":"2006","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pediatrneurol.2008.05.006","article-title":"Lack of valproic acid-associated weight gain in prepubertal children","volume":"39","author":"Espinosa","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.029_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/CON.0000000000000712","article-title":"Antiepileptic drug treatment of epilepsy in children","volume":"25","author":"Moosa","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.029_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2310\/7010.2006.00050","article-title":"Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study","volume":"21","author":"Nicolaidou","year":"2006","journal-title":"J Child Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2019.05.029_bb0040","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00431-008-0672-7","article-title":"Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy","volume":"167","author":"Nettekoven","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.029_bb0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/0883073812443005","article-title":"Antiepileptic drugs and bone metabolism in children: data from 128 patients","volume":"28","author":"Borusiak","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00381-016-3258-0","article-title":"Bone mineral density and vitamin D status in children with epilepsy, cerebral palsy, and cerebral palsy with epilepsy","volume":"33","author":"Tosun","year":"2017","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0055","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pediatrneurol.2010.03.004","article-title":"Prevalence and risk factors for vitamin D insufficiency among children with epilepsy","volume":"42","author":"Shellhaas","year":"2010","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.029_bb0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pediatrneurol.2014.10.008","article-title":"Longitudinal change of vitamin D status in children with epilepsy on antiepileptic drugs: prevalence and risk factors","volume":"52","author":"Lee","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0065","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.412","article-title":"Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass","volume":"26","author":"Baxter-Jones","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.amjmed.2003.12.029","article-title":"Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population based study of younger and older adults","volume":"116","author":"Bischoff-Ferrari","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","article-title":"Bone and calcium metabolism and antiepileptic drugs","volume":"112","author":"Verrotti","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.029_bb0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/derm.20731","article-title":"Influence of drugs on vitamin D and calcium metabolism","volume":"4","author":"Gr\u00f6ber","year":"2012","journal-title":"Dermatoendocrinol"},{"issue":"7","key":"10.1016\/j.yebeh.2019.05.029_bb0085","first-page":"2355","article-title":"The role of receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases","volume":"85","author":"Hofbauer","year":"2000","journal-title":"JCME."},{"key":"10.1016\/j.yebeh.2019.05.029_bb0090","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/j.joms.2011.07.002","article-title":"Synergistic enhancement of new bone formation by recombinanat human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs","volume":"69","author":"Yao","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0095","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1212\/01.wnl.0000247107.54562.0e","article-title":"Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone","volume":"67","author":"Mikati","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-7075-3-36","article-title":"Antiepileptic drugs and bone metabolism","volume":"3","author":"Valsamis","year":"2006","journal-title":"Nutr Metab"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0105","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","article-title":"Changes in serum receptor activator of nuclear factor-kB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1\u201334)","volume":"89","author":"Buxton","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1620\/tjem.226.19","article-title":"Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients","volume":"226","author":"Zheng","year":"2012","journal-title":"Tokushima J Exp Med"},{"issue":"7","key":"10.1016\/j.yebeh.2019.05.029_bb0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1631\/jzus.B1500021","article-title":"Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"J Zhejiang Univ-Sci B (Biomed Biotechnol)"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0120","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1468-1331.2009.02773.x","article-title":"A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy","volume":"17","author":"Verrotti","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/0883073812472256","article-title":"Vitamin D deficiency among children with epilepsy in South Queensland","volume":"29","author":"Fong","year":"2014","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.029_bb0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1469-8749.2009.03402.x","article-title":"Chronic antiepileptic monotherapy, bone metabolism and body composition in non-institutionalized children","volume":"52","author":"Rauchenzauner","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yebeh.2015.06.025","article-title":"The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine","volume":"51","author":"Serin","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-3476(95)70304-7","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"127","author":"Sheth","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition ofcytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.yebeh.2019.05.029_bb0150","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.029_bb0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.toxlet.2010.11.008","article-title":"Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?","volume":"200","author":"Vrzal","year":"2011","journal-title":"Toxicol Lett"},{"issue":"1","key":"10.1016\/j.yebeh.2019.05.029_bb0160","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2008.03.002","article-title":"Predictors of bone density in ambulatory patients on antiepileptic drugs","volume":"43","author":"El-Hajj Fuleihan","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0165","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/seiz.2002.0671","article-title":"Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy","volume":"11","author":"Voudris","year":"2002","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.029_bb0170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/jpem-2006-190411","article-title":"Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3","volume":"19","author":"Kumandas","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.yebeh.2019.05.029_bb0175","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1542\/peds.108.6.e107","article-title":"Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine","volume":"108","author":"Rieger-Wettengl","year":"2001","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.029_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.57.3.445","article-title":"Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy","volume":"57","author":"Sato","year":"2001","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2019.05.029_bb0185","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.yebeh.2003.11.028","article-title":"Treatment of anticonvulsant drug-induced bone disease","volume":"5","author":"Drezner","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.029_bb0190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eplepsyres.2013.06.020","article-title":"Early detection of bone metabolism changes under different antiepileptic drugs(ED-BoM-AED) \u2014 a prospective multicenter study","volume":"106","author":"Bauer","year":"2013","journal-title":"Epilepsy Res"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:28:25Z","timestamp":1761503305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019303610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":38,"alternative-id":["S1525505019303610"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.029","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin D supplementation and bone markers in ambulatory children on long-term valproic acid therapy. A prospective interventional study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}